Icon (NASDAQ:ICLR) Director Sells $138,167.89 in Stock

Icon Plc (NASDAQ:ICLR) Director Linda Grais sold 841 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $138,167.89. Following the sale, the director owned 6,162 shares in the company, valued at approximately $1,012,354.98. The trade was a 12.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Down 2.6%

Shares of NASDAQ:ICLR opened at $163.15 on Friday. The company has a market capitalization of $12.49 billion, a P/E ratio of 38.30, a P/E/G ratio of 6.94 and a beta of 1.21. The stock’s fifty day simple moving average is $162.50 and its 200-day simple moving average is $134.24. Icon Plc has a 52-week low of $66.57 and a 52-week high of $203.91. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The company had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2 billion. During the same period in the previous year, the firm posted $3.26 EPS. Icon’s revenue was up 2.3% on a year-over-year basis. As a group, equities research analysts forecast that Icon Plc will post 9.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Bank of America upped their price target on shares of Icon from $125.00 to $150.00 and gave the stock an “underperform” rating in a research note on Thursday, June 25th. DA Davidson set a $164.00 target price on shares of Icon in a research report on Monday, June 1st. Mizuho boosted their price objective on Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a research report on Friday, June 26th. UBS Group set a $160.00 price objective on Icon in a report on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Icon currently has an average rating of “Hold” and a consensus target price of $170.40.

Institutional Trading of Icon

A number of institutional investors have recently modified their holdings of ICLR. EFG International AG acquired a new position in Icon during the fourth quarter worth $27,000. Abound Financial LLC bought a new stake in Icon in the 4th quarter valued at $54,000. GAMMA Investing LLC lifted its holdings in Icon by 21.4% during the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after purchasing an additional 69 shares during the last quarter. Johnson Financial Group Inc. acquired a new stake in Icon during the third quarter worth approximately $71,000. Finally, Quadrant Capital Group LLC bought a new stake in shares of Icon during the third quarter worth approximately $78,000. 95.61% of the stock is currently owned by institutional investors.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.